Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity

Retina

Volumn 32, Issue 7, 2012, Pages 1250-1259

  Saito, Masaaki ^a   Iida, Tomohiro ^a   Kano, Mariko ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

age related macular degeneration; good baseline visual acuity; indocyanine green angiography; optical coherence tomography; photodynamic therapy; polypoidal choroidal vasculopathy; ranibizumab; retinal pigment epithelial detachment; retinal pigment epithelium; vascular endothelial growth factor

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MALE; OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; THICKNESS; TREATMENT DURATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORING AGENTS; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84862847111     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318236e503     Document Type: Article

References (26)

1. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642. (Pubitemid 15204559)
2. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Oph-thalmol 1991;109:1220-1231.
3. Kvanta A, Algvere PV, Berglin L, Sereqard S. Subfoveal fi-brovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934. (Pubitemid 26324159)
4. Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162. (Pubitemid 27092496)
5. Oh H, Takagi H, Takagi C. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898. (Pubitemid 29365148)
6. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346. (Pubitemid 34250056)
7. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
8. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related mac-ular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
9. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
10. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10: 1-8. (Pubitemid 20201879)
11. Imamura Y, Engelbert M, Iida T, et al. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 2010;55:501-515.
12. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15-22.
13. Lafaut BA, Leys AM, Snyers B, et al. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthal-mol 2000;238:752-759.
14. Tano Y. Ophthalmic PDT Study Group: guidelines for PDT in Japan. Ophthalmology 2008;115:585-585.e6.
15. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92:1642-1647.
16. Saito M, Nagayama D, Iida T. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy: long-term results [in Japanese]. Nippon Ganka Gakkai Zasshi 2009; 113:792-799.
17. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Oph-thalmol 2008;92:70-73.
18. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculop-athy: an interim 6-month report. Br J Ophthalmol 2010;94: 297-301.
19. Tano Y, Ohji M, Ishibashi T, et al. Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase [in Japanese]. Nippon Ganka Gakkai Zasshi 2009;113: 1098-1103.
20. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.
21. Raja MS, Saldana M, Goldsmith C, Burton BJ. Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Br J Ophthalmol 2010;94:1543-1545.
22. Tong JP, Chan WM, Liu DT, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroi-dal neovascularization. Am J Ophthalmol 2006;141:456-462. (Pubitemid 43265948)
23. Barbazetto I, Saroj N, Shapiro H, et al. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010; 30:1376-1385.
24. Treatment of Age-Related Macular Degeneration with Photo-dynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related mac-ular degeneration with verteporfin: one-year results of 2 randomized clinical trials\-TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
25. Visudyne in Minimally Classic CNV (VIM) Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448-457.
26. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macu-lar degeneration clinical and economic impact. Ophthalmology 2010;117:2134-2140.